fbpx

breast

First targeted therapy for HER2-Low breast cancer receives FDA approval

The Food and Drug Administration (FDA) has approved targeted therapy for a newly defined subset of breast cancer. The drug trastuzumab-deruxtecan, also known by the brand name Enhertu, will now be available for people included in the HER2-low breast cancer subtype. HER2 is a protein known as “human epidermal growth factor receptor 2.” It promotes the growth […]

Scroll to top
Social media & sharing icons powered by UltimatelySocial
error

Enjoy this blog? Please spread the word :)